The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Valeant Pharmaceuticals (VRX) agreed to raise their outstanding offer for Salix Pharmaceuticals (SLXP) to $173/share in cash, from a $158 bid announced on January 16th, after Endo International … Continue Reading
Read nowInsights - The big news this weekend out of the American College of Cardiology's annual scientific session was the comparison of long-term outcomes for two new (and competing) drugs targeting cholesterol,
Read nowRecap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.
Read nowResearch - Synergy Pharmaceuticals (SGYP) will shortly report phase 3 data from two large trials of lead candidate plecanatide in Chronic Constipation.
PremiumInsights - Zogenix (ZGNX) is divesting of its lead FDA-approved product, the painkiller Zohydro, for $100 million ($30 million in cash up front) and almost $300 million in potential milestone payments. As much as the cash and milestone potential are important to Zogenix, which is re-positioning itself as a pipeline story, more important is that Zogenix is cutting loose the albatross around its neck for the last year and a half.
Read nowResearch - SAGE Therapeutics (SAGE) and Marinus Pharmaceuticals (MRNS)are innovators in a class of molecules known as neurosteroids and both target epilepsy initially.
PremiumInsights - In yet another uninspiring piece of news for AcelRx (ACRX), the company reported on Monday that the FDA wants another clinical study of the company’s Zalviso patient-controlled analgesic … Continue Reading
Read now
